119th Congress · introduced in the House · Feb 13, 2025
PSA Screening for HIM Act
Official title from Congress.gov
Latest action (Feb 13, 2025): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Feb 13, 2025)
Prostate-Specific Antigen Screening for High-risk Insured Men Act or the PSA Screening for HIM Act
This bill requires private health insurance plans to cover evidence-based, preventive care and screenings for prostate cancer that are not already covered under the recommendations of the U.S. Preventive Services Task Force for certain men.
Specifically, plans must cover such care and screenings for men who are age 40 and over and are at high risk of developing prostate cancer (e.g., with a family history of prostrate cancer). Such coverage must be provided without imposing any cost-sharing requirement.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Cancer · Health care costs and insurance · Health promotion and preventive care · Medical tests and diagnostic methods · Minority health
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
60 citations; showing the 25 most recently posted.
ZERO PROSTATE CANCER · lobbying firm or registrant: ZERO PROSTATE CANCER
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$123,567
Spent on own lobbying
HR 1300/S 293 PSA Screening for HIM Act - eliminating cost sharing for prostate cancer screening Extension of enhanced Advance Premium Tax Credits for Marketplace plan…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ZERO PROSTATE CANCER · lobbying firm or registrant: ZERO PROSTATE CANCER
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Insurance
$123,567
Spent on own lobbying
HR 1300/S 293 PSA Screening for HIM Act - eliminating cost sharing for prostate cancer screening
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DANA-FARBER CANCER INSTITUTE · lobbying firm or registrant: DANA-FARBER CANCER INSTITUTE
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$19,219
Spent on own lobbying
…of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN ASSOCIATION OF NURSE PRACTITIONERS · lobbying firm or registrant: AMERICAN ASSOCIATION OF NURSE PRACTITIONERS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$390,000
Spent on own lobbying
…1482/H.R. 4407 - National Nursing Workforce Center Act of 2025 H.R. 2531/S. 1232 - Workplace Violence Prevention for Health Care and Social Service Workers Act H.R. 1300 - Prostate-Specific Antigen (PSA) Screening for High-risk Insured Men (HIM) Act H.R. 7106 - Enhancing Skilled Nursing Facilities Act H.R. 5629 - To provide tha…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$1,790,000
Spent on own lobbying
…women as well as their providers to better understand breast health. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, H.R. 1300, S. 297. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Pre…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC. · lobbying firm or registrant: ASTELLAS PHARMA US, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$510,000
Spent on own lobbying
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC. · lobbying firm or registrant: ASTELLAS PHARMA US, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$510,000
Spent on own lobbying
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills)…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DANA-FARBER CANCER INSTITUTE · lobbying firm or registrant: DANA-FARBER CANCER INSTITUTE
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$36,000
Spent on own lobbying
…of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN ASSOCIATION OF NURSE PRACTITIONERS · lobbying firm or registrant: AMERICAN ASSOCIATION OF NURSE PRACTITIONERS
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$400,000
Spent on own lobbying
…1482/H.R. 4407 - National Nursing Workforce Center Act of 2025 H.R. 2531/S. 1232 - Workplace Violence Prevention for Health Care and Social Service Workers Act H.R. 1300 - Prostate-Specific Antigen (PSA) Screening for High-risk Insured Men (HIM) Act H.R. 7106 - Enhancing Skilled Nursing Facilities Act H.R. 5629 - To provide tha…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$1,240,000
Spent on own lobbying
…women as well as their providers to better understand breast health. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, H.R. 1300, S. 297. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Pre…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ZERO PROSTATE CANCER · lobbying firm or registrant: ZERO PROSTATE CANCER
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Health Issues
$123,655
Spent on own lobbying
HR 1300/S 293 PSA Screening for HIM Act - eliminating cost sharing for prostate cancer screening Extension of enhanced Advance Premium Tax Credits for Marketplace plan…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ZERO PROSTATE CANCER · lobbying firm or registrant: ZERO PROSTATE CANCER
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Insurance
$123,655
Spent on own lobbying
HR 1300/S 293 PSA Screening for HIM Act - eliminating cost sharing for prostate cancer screening
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC · lobbying firm or registrant: THEGROUP DC, LLC
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$70,000
Paid to lobbying firm
H.R. 1300, PSA Screening for HIM Act Prostate-Specific Antigen Screening for High-risk Insured Men Act Issues related to the treatment of menopause and womens health at…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC · lobbying firm or registrant: THEGROUP DC, LLC
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Pharmacy
$70,000
Paid to lobbying firm
H.R. 1300, PSA Screening for HIM Act Prostate-Specific Antigen Screening for High-risk Insured Men Act Issues related to the treatment of menopause and womens health at…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC. · lobbying firm or registrant: ASTELLAS PHARMA US, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Medicare/Medicaid
$590,000
Spent on own lobbying
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC. · lobbying firm or registrant: ASTELLAS PHARMA US, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$590,000
Spent on own lobbying
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills)…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DANA-FARBER CANCER INSTITUTE · lobbying firm or registrant: DANA-FARBER CANCER INSTITUTE
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$50,000
Spent on own lobbying
…of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN ASSOCIATION OF NURSE PRACTITIONERS · lobbying firm or registrant: AMERICAN ASSOCIATION OF NURSE PRACTITIONERS
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$400,000
Spent on own lobbying
…2025. S. 1482 - National Nursing Workforce Center Act of 2025 H.R. 2531/S. 1232 - Workplace Violence Prevention for Health Care and Social Service Workers Act H.R. 1300 - Prostate-Specific Antigen (PSA) Screening for High-risk Insured Men (HIM) Act H.R. 7106 - Enhancing Skilled Nursing Facilities Act H.R. 5629 - To provide tha…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$2,300,000
Spent on own lobbying
…women as well as their providers to better understand breast health. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, H.R. 1300, S. 297. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Pre…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ZERO PROSTATE CANCER · lobbying firm or registrant: ZERO PROSTATE CANCER
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 17, 2026 · issue area: Health Issues
$220,000
Spent on own lobbying
HR 1300/S 293 PSA Screening for HIM Act - eliminating cost sharing for prostate cancer screening Extension of enhanced Advance Premium Tax Credits for Marketplace plan…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ZERO PROSTATE CANCER · lobbying firm or registrant: ZERO PROSTATE CANCER
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 17, 2026 · issue area: Insurance
$220,000
Spent on own lobbying
HR 1300/S 293 PSA Screening for HIM Act - eliminating cost sharing for prostate cancer screening, extension of enhanced Advance Premium Tax Credits for Marketplace pla…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DANA-FARBER CANCER INSTITUTE · lobbying firm or registrant: DANA-FARBER CANCER INSTITUTE
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · amended · posted Jan 21, 2026 · issue area: Health Issues
$89,000
Spent on own lobbying
…of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC · lobbying firm or registrant: THEGROUP DC, LLC
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 21, 2026 · issue area: Health Issues
$70,000
Paid to lobbying firm
H.R. 1300, PSA Screening for HIM Act Prostate-Specific Antigen Screening for High-risk Insured Men Act Issues related to the treatment of menopause and womens health at…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC · lobbying firm or registrant: THEGROUP DC, LLC
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 21, 2026 · issue area: Pharmacy
$70,000
Paid to lobbying firm
H.R. 1300, PSA Screening for HIM Act Prostate-Specific Antigen Screening for High-risk Insured Men Act Issues related to the treatment of menopause and womens health at…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$2,380,000
Spent on own lobbying
…disparities and advance health equity in breast and cervical cancer. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, H.R. 1300, S. 297. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Pre…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing